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PRINCIPLES: Statin therapy reduces cardiovascular mor-
bidity and mortality. However, a substantial residual car-
diovascular risk can be observed in patients receiving this
therapy due to persisting lipid abnormalities as well as to
the lack of a systematic global risk-reduction strategy. The
objective of the study was to assess the prevalence of dys-
lipidemia in a cohort of patients living in Switzerland and
receiving statin therapy.
METHODS: This cross-sectional study was conducted by
61 primary care physicians, cardiologists, endocrinologists
and internists in Switzerland. Patients were consecutive
outpatients ≥45 years-old, on statin therapy for at least 3
months with available lipid values. A clinical examination
and a recording of the latest lipid values on statin therapy
were performed in all patients.
RESULTS: A total of 473 patients (age 66.3 ± 9.41 years;
61.9% male) were included in the final analysis.
Under statin therapy, 40% of the analysed patients had a
normal lipid profile, 32.6% presented increased low-dens-
ity lipoprotein cholesterol (LDL-C) (3.35 ± 0.88 mmol/
L), 28.8% low high-density lipoprotein-cholesterol (HDL-





CHD: coronary artery disease
FOCUS: Focus on Comprehensive Lipid Management Survey in
Swiss Patients
CVD: cardiovascular disease
(2.69 ± 1.04 mmol/L). It is of note that the included popula-
tion was characterised by a high prevalence of cardiovascu-
lar risk factors (86.5% patients had 10-year cardiovascular
risk >20%). Nevertheless, the lipid lowering therapy was
modified in only 15.4% of the patients.
CONCLUSION: Persistent dyslipidemia is a reality in
statin-treated patients and may contribute to their residual
cardiovascular risk. Therefore, comprehensive lipid man-
agement should be preferred to aggressive LDL-C lower-
ing alone. Moreover, strategies to assess and modify the
global cardiovascular risk of patients should be taken into
account as an important component of primary and second-
ary prevention.
Key words: statin; residual cardiovascular risk; lipid
profile
Introduction
Primary and secondary prevention studies have shown that
the use of statins is associated with significant reductions
in cardiovascular morbidity and mortality [1–5, 6–8].
A recently published meta-analysis [9] analysing the res-
ults of 76 randomised control trials involving 170’255 par-
ticipants showed that statin therapy was associated with a
substantial reduction of all-cause mortality (Relative Risk
(RR) 0.90), cardiovascular disease (CVD) mortality (RR
0.80), fatal and non-fatal myocardial infarction (MI) (RR
0.82 and 0.74 respectively), revascularisation (RR 0.76),
and a composite of fatal and non-fatal strokes (RR 0.86).
However, around 70% of cardiovascular events occur des-
pite treatment with statins [10, 11].
This residual cardiovascular risk may be partially ex-
plained by un-modifiable cardiovascular risk factors such
as age, gender and a family history of cardiovascular dis-
eases, as well as by an insufficient treatment of risk factors
other than dyslipidemia such as smoking, arterial hyperten-
sion, diabetes and a sedentary lifestyle.
Moreover, therapy with statins is not sufficient for a com-
prehensive lipid management.
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Many epidemiologic studies have documented the strong
inverse correlation between high-density lipoprotein-cho-
lesterol (HDL-C) levels and cardiovascular morbidity and
mortality.
A post hoc analysis of the recently completed study Treat-
ing to New Targets (TNT) [12] showed that low levels
of HDL-C and raised triglyceride (TG) levels are strongly
linked to a significantly increased risk of coronary heart
disease (CHD) even in patients who achieve the current
low-density lipoprotein cholesterol (LDL-C) targets. A re-
cent analysis of The PROspective CArdiovascular Munster
(PROCAM), the REsiduAl risk LIpids and Standard Ther-
apies (REALIST) surveys presented at the annual meeting
of the European Society of Cardiology showed that when
all risks factors were matched, the odds of experiencing a
MI were increased five-fold for men with a LDL-C at the
target level (less than or equal to 100 mg/dL), presenting
a low level of HDL-C (<45 mg/dL) and an elevated level
of TG (>150 mg/dL) [13]. Moreover, the Interheart study
identified that the imbalance between atherogenic and ath-
eroprotective lipoproteins was the most powerful poten-
tially modifiable risk factor for CVD [14].
At the present time, less data are available on the effect of
increasing HDL on cardiovascular risk.
In a meta-analysis analysing the data from the Coronary
Primary Prevention Trial, the Multiple Risk Factor Inter-
vention Trial, the Lipid Research Clinics Prevalence
Mortality Follow-up Study and the Framingham Heart
Study, for every 1-mg/dL (0.026 mmol/L) increase in
plasma HDL cholesterol in the populations studied, there
was a decrease in CHD risk of approximately 2% in men
and 3% in women independent of other risk factors, includ-
ing plasma LDL cholesterol [15].
Similarly a re-analysis of the Armed Forces Regression
Study [16] suggested that in a population of patients with
stable atherosclerosis, the greater the percentage increase in
HDL achieved, the greater the cardio-protective benefit.
Moreover, a very recently published study showed, in the
Framingham population, that a low HDL-C level was asso-
ciated with a 40% increase in the incidence of heart failure
independently of its association with myocardial infarction
[17].
Beside HDL-C, some epidemiological studies have sug-
gested that hypertriglyceridemia is also associated with in-
creased cardiovascular morbidity and mortality.
A meta-analysis of 17 population-based prospective studies
involving 46’413 men and 10’864 women indicated that
TG levels were associated with a significant increase of
32% and 76%, respectively, in cardiovascular risk based
on univariate analysis. This association remained signific-
ant even after adjustment for HDL-C [18].
Concerning the effect of therapy, treatment of elevated TG
in clinical trials has been shown to reduce cardiovascular
events, cardiac deaths and total mortality [19, 20].
However, the association between TG and cardiovascular
disease is more modest compared to one of the other risk
factors and the role of TG in cardiovascular prevention is
controversial.
In particular, it is unclear whether hypertriglyceridemia
should be considered an independent predictor of coronary
events or an indicator of the presence of a cluster of cardi-
ovascular factors such as the metabolic syndrome [11].
Moreover, it is of note that lipids, and in particular HDL
and TG, have a different impact on cardiovascular health in
males and females [21, 22].
The Focus on Comprehensive Lipid Management Survey
in Swiss Patients (FOCUS) aimed to evaluate the control
of lipid profile and the cardiovascular risk in patients aged
≥45 years and under treatment with a statin for at least three
months before inclusion.
Methods
Data sources and subjects
The FOCUS Study took place in Switzerland from July
2008 to June 2009.
This cross-sectional epidemiological survey was conducted
by 61 cardiologists, endocrinologists, internists and
primary care physicians in Switzerland.
Physicians were asked to screen outpatients older than 45
years, who had been on statin therapy for at least 3 months.
A clinical history (including gender, age, history of athero-
thrombotic events, risk factors and family history) as well
as a clinical examination and the recording of the latest lip-
id values on statin therapy were required in all patients.
Laboratory data were abstracted from patients’ charts, un-
der the actual statin therapy and were not older than 12
months.
Patients with a history of cancer, hepatic or renal diseases
and endocrinological disease other than diabetes were ex-
cluded from the study.
The local ethical committee approved the study. Parti-
cipants signed an informed consent form, were informed
about the results and, if necessary, they were advised to
modify their lifestyle/medical therapy.
Definition of dyslipidemia
Total cholesterol (TC), HDL-C, LDL-C and TG were
measured in venous or capillary blood. If LDL-C was not
available and triglycerides were lower than 4.5 mmol/L,
the LDL-C value was calculated using the Friedewald for-
mula (LDL-C=TC - HDL-C – (Triglycerides/2.2)).
According to the recommendations of the National Cho-
lesterol Educational Program for fasting testing conditions
[23], we defined “High LDL-C” as LDL-C ≥2.6 mmol/L
for patients at high risk, ≥3.4 mmol/L for patients at inter-
mediate risk and ≥4.1 mmol/L for low risk patients. “Low
HDL-C” was defined as HDL-C <1.3 mmol/L in women
and < 1 mmol/L in men, and “elevated triglycerides” were
defined as ≥1.7 mmol/L for patients with diabetes and/or
metabolic syndrome and as ≥5.0 mmol/L for the other pa-
tients.
Definition of diabetes mellitus
Criteria for the diagnosis of diabetes mellitus were an es-
tablished disease of diabetes or casual plasma glucose
greater than 11 mmol/l.
Original article Swiss Med Wkly. 2011;141:w13200
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 2 of 7
Definition of arterial hypertension
Criteria for the diagnosis of arterial hypertension were a
previous or current diagnosis, defined according to the cur-
rent guidelines [24, 25].
Definition of current cigarette smoking
Current smokers were identified by the questions “Have
you ever smoked and did you stop more than 1 year ago?
Do you currently smoke every day, some days, or not at
all?” as recommended by the National Centre for Health
Statistics for estimates of smoking prevalence.
Measurement of Body Mass Index and waist
circumference
The body mass index was calculated by dividing a person’s
weight in kilograms by their height in meters squared. Be-
ing overweight and obesity were defined as a body mass
index greater than 25 and 30, respectively. Waist circum-
ference was measured at a level midway between the lower
rib margin and the iliac crest with the tape all around the
body in a horizontal position.
Definition of metabolic syndrome
Subjects with a metabolic syndrome were defined accord-
ing to the International Diabetes Federation (IDF) defini-
tion [26] as patients presenting 3 or more of the following
factors:
– Waist circumference >88 cm in females and <102 in
males
– HDL-C <1.3 mmol/L in women and <1 mmol/L in men
– TG ≥1.7 mmol/L
– Systolic blood pressure ≥130 mm Hg
– Diastolic blood pressure ≥85 mm Hg
– Plasma glucose ≥6.1 mmol/L
Cardiovascular risk
The 10-year risk for a cardiovascular event was calculated
according to the algorithms based on the data of the
PROCAM Study [27] and was adapted for the Swiss pop-
ulation by the AGLA (Arbeitsgruppe Lipide und Atherosk-
lerose of the Swiss society of cardiology; www.agla.ch).
According to the European guidelines [28, 29], patients
were divided into “low risk “(10-year risk <10%), “in-
termediate risk” (10-year risk 10–20%) and a “high risk”
(10-year risk >20%).
Statistical analysis
Continuous variables are expressed as mean ± standard de-
viation. Categorical variables are expressed as frequencies
and percentages. Comparisons between categorical vari-
ables were performed using 2-sided Pearson chi-square
statistic. A probability of less than 0.05 was considered
statistically significant. Statistical analysis was performed
using SPSS™ software version 15.0.
Results
Overall 2’787 patients were screened, and 506 patients
were recruited for the study by 59 physicians. As a com-
plete lipid profile was not available for 33 patients, the final
analysis was done with 473 patients (fig. 1).
The clinical characteristics of the patients included in the
study overall and divided according to gender and low and
high cardiovascular risk are shown in table 1. The lipid
lowering drugs used at baseline are shown in table 2.
Figure 1
Flow chart of the Focus on Comprehensive Lipid Management
Survey in Swiss Patients.
Figure 2
Abnormalities of the lipid profile found in the 473 patients included
in the final analysis.
LDL-C: low density lipoprotein-cholesterol, TG: triglycerides, HDL-
C: high density lipoprotein-cholesterol. High LDL-C was defined as
LDL-C >2.6 mmol/L high risk patients, LDL-C ≥4.1 mmol/L in
patients with low cardiovascular risk; low HDL-C was defined as
HDL-C <1.3 mmol/L in women or <1 mmol/L in men; high TG were
defined as TG ≥1.7 mmol/L in high risk patients and ≥5.0 mmol/L in
patients with low or intermediate risk.
Figure 3
Change of lipid modifying treatment based on the laboratory results
from the 473 patients included in the final analysis.
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The patients included in the final analysis were recruited by
59 physicians working in Switzerland (45.9% in the Ger-
man part and 54.1% in the French/Italian part).
A total of 40.7% of the patients were treated by endo-
crinologists or diabetes specialists, 33.9% by cardiologists,
18.6% by internal medicine specialists, 5.1% by specialists
in angiology and 1.7% by nephrologists.
Cardiovascular risk
The FOCUS study population was characterised by a high
prevalence of cardiovascular risk factors (table 3). A family
history of cardiovascular disease was reported in 146 pa-
tients (30.9%), 70 were current smokers and 133 patients
were previous smokers (14.8% and 28.1% respectively);
a diagnosis of dyslipidemia was reported in 443 patients
(93.7%, 9.7% defined as “familiar dyslipidemia”), arterial
hypertension was reported in 357 patients (75.5%), and a
diagnosis of diabetes mellitus in 257 patients (54.3%). A
metabolic syndrome was diagnosed according to the IDF
criteria in 145 patients (30.7%).
According to this high prevalence of risk factors, we found
that 86.5% of the population had a 10-year cardiovascular
risk higher than 20%.
A total of 45% of the patients had a previous diagnosis
of coronary artery disease, 7.6% of heart failure, 12.1% of
a cerebrovascular disease, and 12.1% had a previous dia-
gnosis of peripheral artery disease.
Lipid profile
As required by the inclusion criteria, all the patients were
treated with a statin.
The mean lipid values by gender and the cardiovascular
risk class are shown in table 1.
The alterations were similar in patients with a high cardi-
ovascular risk and patients with CHD, while patients with
diabetes were more frequently characterised by high TG
level (table 4).
It is of note that under statin therapy only 40% of the pa-
tients included in the FOCUS Study had a lipid profile
within the recommended limits.
The abnormalities of the lipid profile found in the FOCUS
population are shown in figure 2. It is of note that 27.5%
of the patients presented a normal LDL-C associated with
low HDL-C or high TG, high LDL-C with normal HDL-
C and triglycerides was found in 16.1%, and the combina-
tion of high LDL-C, low HDL-C and high TG was found
in 16.5%.
A low HDL was more frequently found in patients younger
than 65 years (33.2% vs 24.8%, p = 0.044), and in patients
with diabetes mellitus (32.7% vs 24.1%, p = 0.039) or with
a metabolic syndrome (61.4 vs 14.3%, p <0.001).
High TG were more frequent in patients with diabetes mel-
litus (46.7% vs 12.5%, p <0.001) or with a metabolic syn-
drome (78.6 vs 10.1%, p <0.001).
Changes in the lipid lowering therapy
The physicians were asked to change the therapy if neces-
sary and to define which parameters were important in the
decision for changing.
Even though around 60% of the patients did not reach one
or more lipid-targets (as defined in the method section ac-
cording to the current guidelines), the therapy was changed
in only 15.4% of the patients (fig. 3).
The treating specialists modified the lipid lowering therapy
as follows: they changed the statin (2.1%), increased the
doses of the statin (7.8%), prescribed an additional drug
(2.7%) and they started another intervention (2.8%) (fig.
3).
A total of 81.4% of the physicians changed their thera-
peutic strategies because LDL-C was higher than the thera-
peutic goal, 67% because HDL-C was low, 66.6% changed
the therapy from looking at total cholesterol and 59% be-
cause triglycerides were elevated. Just a third of physicians
(36.2%) considered the TC/HDL-C ratio as relevant.
The values given to the different parameters differed not-
ably according to the patient groups and to the speciality of
the physicians.
In patients with diabetes mellitus, LDL-C (87.5% vs.
74.1%, p = 0.001), HDL-C (76.3% vs. 56%, p <0.001) and
TG (68.9% vs. 47.2%, p <0.001) were considered more im-
portant in order to modify the therapy, compared to non-
diabetic patients.
On the contrary, HDL-C and TG levels were considered
more relevant in the absence of CHD (HDL-C 76.9% vs.
54.9%, p <0.001; TG 66.5% vs. 49.8%, p = 0.001), while
LDL-C was considered similarly in patients with or
without CHD (77.5% vs. 84.6%, respectively, p = 0.096).
Plasma glucose (62.6% vs. 38.9%, p <0.001) and HbA1c
(70.4% vs. 14.4%, p <0.001) were considered to be relev-
ant more in diabetic patients than in non-diabetic patients.
Gender differences
Lipids play a different role as a cardiovascular risk factor
according to gender. LDL-C seems to be a less important
risk factor in pre-menopausal women; HDL-C is a better
predictor of risk in women than in men, and TG are an in-
dependent predictor of CAD risk in post-menopausal wo-
men [22].
Therefore we analysed the data of the FOCUS population
according to gender.
In this study, 180 female and 293 male were included. A
total of 162 female (90%) were in post-menopausal status.
Coronary artery disease was significantly more prevalent in
men compared to women (56.7% vs. 26.1%, p <0.001).
The prevalence of hypertension, diabetes, metabolic syn-
drome and dyslipidemia was similar in male and female pa-
tients.
A lipid profile within the normal limits was found in 38.9%
of male patients and in 41.7% of females.
A LDL-C at a goal level associated with other abnormal-
ities in the lipid profile (low HDL-C and/or high TG) was
found in 27% of males and in 28.3% of the female patients.
Even the mean HDL was higher in females (1.45 ± 0.41)
than in males (1.23 ± 0.36) (p = 0.019).
The prevalence of high triglycerides was similar in both
genders (28.3% in females vs. 32.8% in males, p = ns).
Discussion
Switzerland is a country characterised by a low risk for
cardiovascular morbidity and mortality, and from 1970 to
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2004 the mortality rate for ischemic heart disease dimin-
ished from 76.4/ to 51.3/100’000 persons [30].
Nevertheless, cardiovascular disorders are still the leading
cause of death. In 2007, in Switzerland 10’107 of 29’544
Table 1: Baseline characteristics of the study population.
Clinical characteristics All Gender Cardiovascular risk
Female Male <10% <20%
Gender (female/male) 180/293
Age (years) 66.3 ± 9.41 67.3 ± 9.98 65.8 ± 9.01 65.2 ± 11.5 66.5 ± 9.13
BMI (kg/m2) 28.5 ± 4.96 28.6 ± 5.5 28.4 ± 4.6 26.5 ± 4.1 28.7 ± 5.0
Systolic blood pressure (mm Hg) 138.8 ± 16.7 139.7 ± 16.2 138.4 ± 17.1 133.8 ± 12.6 139.3 ± 17.1
Diastolic blood pressure (mm Hg) 81.4 ± 9.7 82.8 ± 8.5 80.6 ± 10.3 82.4 ± 8.8 81.2 ± 9.8
Total cholesterol (mmol/L) 4.52 ± 1.04 4.73 ± 0.98 4.39 ± 1.05 4.75 ± 0.82 4.48 ± 1.06
LDL cholesterol (mmol/L) 2.45 ± 0.9 2.56 ± 0.86 2.37 ± 0.92 2.65 ± 0.7 2.41 ± 0.9
HDL cholesterol (mmol/L) 1.31 ± 0.4 1.45 ± 0.41 1.23 ± 0.36 1.47 ± 0.3 1.29 ± 0.4
Triglycerides (mmol/L) 1.71 ± 0.99 1.58 ± 0.78 1.79 ± 1.1 1.42 ± 0.71 1.75 ± 1.02
Plasma glucose (mmol/L) 6.7 ± 2.18 6.56 ± 1.93 6.79 ± 2.31 5.33 ± 0.9 6.9 ± 2.24
HbA1c (%, in diabetics only) 6.97 ± 1.34 6.94 ± 1.34 6.99 ± 1.35 5.5 ± 0.63 7.09 ± 1.32
LDL: low density lipoprotein, HDL: high density lipoprotein
Table 2: Lipid lowering drugs at baseline.
Drugs Number of patients (%) Mean doses
Atorvastin 201 (42.5) 30 mg
Fluvastatin 17 (3.6) 53 mg
Pravastatin 89 (18.8) 32 mg
Rosuvastatin 25 (5.3) 12 mg
Simvastatin 141 (29.8) 30 mg
Any statin + ezetimibe 27 (5.7%)
Any statin + fibrate 4 (0.8%)
Any statin + niacin 1 (0.2%)
Table 3: Prevalence of cardiovascular risk factors in the study population.













Table 4: Lipid profile alterations found in the study population with high cardiovascular risk.
Lipid profile (patients with cardiovascular risk >20%) Absolute number, percentage
No lipid alterations 136/409, 33.3%
LDL-C >2.6 mmol/L 151/409, 36.9%
Low HDL-C 126/409, 30.8%
High triglycerides 147/409, 35.9%
Lipid profile (patients with history of CHD)
No lipid alterations 75/213, 35.2%
LDL-C >2.6 mmol/L 74/213, 34.7%
Low HDL-C 66/213, 31.0%
High triglycerides 72/213, 33.8%
Lipid profile (patients with diabetes)
No lipid alterations 75/257, 29.2%
LDL-C >2.6 mmol/L 86/257, 33.5%
Low HDL-C 84/257, 32.7%
High triglycerides 120/257, 46.7%
LDL-C: low density lipoprotein-cholesterol, TG: triglycerides, HDL-C: high density lipoprotein-cholesterol; CHD: coronary heart disease. High LDL-C was defined as LDL-C
>2.6 mmol/L high risk patients, LDL-C ≥4.1 mmol/L in patients with low cardiovascular risk; low HDL-C was defined as HDL-C <1.3 mmol/L in women or <1 mmol/L in men;
high triglycerides were defined as triglycerides ≥1.7 mmol/L in high risk patients and ≥5.0 mmol/L in patients with low or intermediate risk. Cardiovascular risk was
defined according to the European guidelines [28, 29]. We divided patients into “low risk “(10-year risk <10%), “intermediate risk” (10-year risk 10–20%) and “high risk”
(10-year risk >20%).
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deaths in men and 12’506 of 31’545 deaths in women were
caused by cardiovascular disease [31].
Well-organised and focused primary and secondary preven-
tion therefore have the potential to change the fate of thou-
sands of people in Switzerland.
Reducing LDL-Cholesterol reduces cardiovascular risk in
patients with or without cardiovascular disease (CVD) and
epidemiological data have suggested that increasing HDL
and reducing triglycerides could be beneficial in terms of
reducing cardiovascular risk. Checking and, if necessary,
treating lipid profiles is one of the most important strategies
for an effective prevention of CVD [29].
The use of statins is a cornerstone in the secondary preven-
tion of CVD and it is associated with a substantial reduc-
tion in cardiovascular morbidity and mortality [23, 29].
Moreover, a recent meta analysis of a trial enrolling pa-
tients with cardiovascular risk factors but without estab-
lished CVD, showed that the use of statins was associated
with a significantly improved chance of survival and large
reductions in the risk of major cardiovascular events [32].
Nevertheless, patients treated with statins still have a con-
sistent “residual risk” [10, 11].
Even if part of this residual risk may be explained by non-
modifiable risk factors, we have the possibility to reduce
it by an effective and comprehensive treatment of all the
components of the lipid profile and by a simultaneous treat-
ment of the different cardiovascular risk factors.
In the FOCUS study, we observed that only 40% of the pa-
tients had a normal lipid profile even if they were all treated
by a statin. Moreover, many patients with a LDL-C level
below the target for primary or secondary prevention were
characterised by a low HDL-C, and/or high TG.
Two main data from the FOCUS study should be high-
lighted:
Firstly, a change in therapy only occurred in a quarter of the
patients with an abnormal lipid profile and secondly, altera-
tions of the lipid profile other than LDL-C levels were less
often taken into consideration by the physicians in order
to decide a therapeutic change. HDL-C and TG were con-
sidered to be relevant for changing the therapy in the pres-
ence of diabetes mellitus or metabolic syndrome as well as
in patients without CHD or with a low cardiovascular risk.
The parameters taken into account by the physicians for
changing the therapy did not differ by age, gender or geo-
graphic area.
Last but not least, it is of note that if a change in therapy
was done, it was mainly an increase in the statin doses
even though this strategy was shown to be associated with
small incremental reductions in the cholesterol level. In
fact, doubling the dose of a statin lowers LDL-cholesterol
by an additional 6% [33].
When investigating gender related differences, we found
that, in the population included in the FOCUS study, the
prevalence of CHD was significantly higher in male pa-
tients compared to females. Moreover, females presented
a higher HDL compared to males but a significant higher
percentage of them were classified as low HDL-C probably
due to the higher cut-off. Nevertheless, the importance of
HDL-C level was equal among males and females.
Limitations
The FOCUS study included a selected population charac-
terised by previous treatment with a statin. This inclusion
criterion may be responsible for the high prevalence of
dyslipidemia and high cardiovascular risk observed in the
enrolled population. Moreover, the fact that the majority
of recruiting physicians were endocrinologists or diabetes
specialists may explain the high prevalence of diabetes
mellitus and metabolic syndrome seen in the study popula-
tion.
Therefore the data collected in the FOCUS study should
not be generalised to an unselected Swiss population.
Conclusions
Evidence linking statins to cardiovascular risk protection
and reduced mortality is clear and consistent across all
adult age groups and it extends to individuals with cardi-
ovascular disease and with cardiovascular risk factors.
Reducing the residual cardiovascular risk in patients
treated with statins remains an exciting clinical challenge.
Comprehensive lipid management and a global reduction
of the whole cardiovascular risk should be considered as
winning strategies to improve the prognosis of statin-
treated patients.
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